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Abstract 
Systemic lupus erythematosus (SLE) is an autoimmune disorder of a largely 
unknown aetiology. Anti-double stranded DNA antibodies (anti-dsDNA) are a 
classical hallmark of the disease, the mechanism underlying their induction 
remains unclear. We demonstrate here that, in lupus-prone and normal mouse 
strains, strong anti-dsDNA antibody responses can be induced by dendritic cells 
(DCs) that have ingested syngeneic necrotic (DC/nec), but not apoptotic 
(DC/apo), cells. Clinical manifestations of lupus were evident however only in 
susceptible mouse strains, which correlate with the ability of DC/nec to release 
IFN-γ and to induce the pathogenic IgG2a anti-dsDNA antibodies. Injection of 
DC/nec not only accelerated disease progression in the MRL/MpJ-lpr/lpr lupus-
prone mice but also induced a lupus-like disease in the MRL/MpJ-+/+ wild-type 
control strain. Immune complex deposition was readily detectable in the kidneys, 
and the mice developed proteinuria. Strikingly, female MRL/MpJ-+/+ mice that 
had received DC/nec, but not DC/apo, developed a ‘butterfly’ facial lesion 
resembling a cardinal feature of human SLE. Our study therefore demonstrates 
that DC/nec inducing a Th1 type of responses, which are otherwise tightly 
regulated in a normal immune system, may play a pivotal role in SLE 
pathogenesis. 
 
 
 
 
 
Introduction 
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SLE is a prototypic systemic autoimmune disease characterized by the production of a 
variety of autoantibodies which are directed predominantly against nuclear antigens 
[1]. In both SLE patients and the lupus mouse models, the presence of anti-DNA 
antibodies, especially anti-dsDNA antibodies, is closely correlated with clinical 
disease and hence of diagnostic and even prognostic value [2]. Purified native 
mammalian DNA is however a weak immunogen [3, 4]. It is not clear whether these 
anti-DNA responses are induced against somatic DNA, or represent cross-reactivity 
of the antibodies to pathogens – ‘molecular mimicry’ [5], or an ‘anti-idiotypic 
response’ [6]. A recent model proposes that some uncommon modifications or 
handling of self-tissue components, including nucleic acids, may explain such altered 
auto-antigenicity, and that the modified self-antigens are most likely to originate from 
dying cells [7-10]. The macrophage-mediated mechanism for removal of dying cells 
is defective in some autoimmune diseases including SLE [11]. As a consequence, 
dying cells (e.g. following infection or even due to normal tissue/cell turnover) 
accumulate and the cellular contents normally-shielded from the adaptive immune 
system may be released acting as the “auto-antigens”. A key question is still however 
“what is the process that renders DNA ‘immunogenic’?”. 
 
DCs are potent antigen presenting cells (APC) playing a key role in the initiation of 
immune responses, and they may take up dying cells for antigen processing and 
presentation [12]. We report here that DCs loaded with necrotic cells (DC/nec) but not 
apoptotic cells (DC/apo) are powerful inducers of anti-DNA antibody response. 
Injection of syngeneic DC/nec not only accelerated disease progression in the 
MRL/MpJ-lpr/lpr (MRL/lpr) lupus-prone mice but also induced a lupus-like disease 
in the MRL/MpJ-+/+ (MRL/+) wild-type control strain. However, despite the fact that 
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high levels of anti-dsDNA antibodies were also detected in the DC/nec-treated 
C57BL/6 mice, these animals failed to develop clinical disease. We show further 
evidence indicating that the isotype of anti-dsDNA antibodies are also critical. The 
DC-induced pathological changes in susceptible mouse strains correlate closely with 
the ability of these cells to mediate a Th1 type of response. This includes the release 
of high levels of IFN-γ and reduced level of IL-10 in vitro and, more importantly, the 
preferential induction of pathogenic IgG2a anti-dsDNA autoantibodies that readily 
form renal immune complex deposits in vivo.  
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Results 
Anti-DNA antibody responses. 
To test the hypothesis that anti-DNA responses can be induced by DCs that had 
captured nuclear antigens in the form of dying cells leading to lupus disease, we 
generated DCs from mouse bone marrow. The cells were then allowed to phagocytose 
either necrotic or apoptotic splenocytes in vitro, before being injected intravenously 
into syngeneic young mice (see Methods). Three strains of mice were tested: the 
MRL/lpr strain which carries a defective Fas gene and develops a spontaneous lupus-
like disease as they age [13, 14], the wild-type MRL/+ strain that express intact Fas, 
and a normal inbred C57BL/6 strain. After injection of the DCs pre-loaded with 
necrotic cells into young mice at 5-weeks of age, highly though transiently elevated 
serum anti-dsDNA was detected in the MRL/lpr, but not the MRL/+ (<30U/ml), 
strain (Data not shown). However, when DC/nec were injected into adult mice (11 
weeks of age), strong and rapid anti-dsDNA responses were detected not only early in 
the MRL/lpr lupus mouse strain, but also in the wild-type MRL/+ as well as the 
C57BL/6 control strains (Fig. 1, filled circles). In particular, sera from the adult 
female MRL/+ mice 4 weeks after treatment with DC/nec contained anti-dsDNA 
antibodies at levels comparable with that of aged (>6-month) and terminally-ill 
MRL/lpr lupus mice (Fig. 1, histograms as indicated). In contrast, when the mice 
were injected with DCs loaded with apoptotic cells (Fig. 1, filled triangles, and 
histogram labelled DC/apo), levels of anti-dsDNA antibodies were significantly lower, 
similar to the mice treated with DCs alone (histogram labelled DC). DC may become 
activated by the handling process or they may take up some dying cells derived during 
DC generation accountable for the small amount of antibodies induced. Minimal 
amounts of serum anti-dsDNA antibodies were detected in the groups treated with 
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necrotic cells alone (Nec), apoptotic cells alone (Apo), PBS or untreated controls (Fig. 
1, open circles and histograms indicated). In the MRL/lpr strain, however, the 
differences between DC/nec and DC/apo-treated groups or the treated groups over the 
untreated control group were less clear due to higher individual variability within the 
treated groups and the spontaneous age-dependent anti-DNA antibody production in 
the control group. Nevertheless, compared to the control MRL/lpr mice at some time 
points tested, the DC/nec-treated group displayed significantly higher serum anti-
dsDNA levels, whereas the DC/apo-treated group displayed decreased levels (* Fig. 1, 
lower left panel, n = 5). The kinetics of DC-induced anti-DNA responses was similar 
in both female and male mice, but the levels were in general lower in the males (data 
not shown). Serum anti-single stranded DNA antibody (anti-ssDNA) were also highly 
elevated in the DC/nec-treated MRL/+ mice which correlated kinetically and 
proportionally with the anti-dsDNA levels (data not shown).  
 
Lupus-like facial skin lesions. 
One of the typical clinical manifestations of human lupus is the facial erythema, the 
so-called ‘butterfly rash’. In Latin, the term ‘lupus’ means wolf and it has been used 
since mediaeval time to describe the erythemic ulcerations which could ‘eat away’ the 
face [15]. We first noticed that adult female MRL/+ mice (wild-type control MRL 
strain) that had received 3 injections of DC/nec, uniformly developed ‘butterfly’ facial 
skin lesions resembling the human butterfly rash (Fig. 2a-b). The facial lesions started 
at around 3-months post-injection of DCs with hair loss, some presented with ear and 
eye lesions, and by 4-months all female mice in the group developed such lesions to 
different degrees (Fig. 2a, upper panel). By around 5-months post-injection, the 
lesions developed extensively extending above the eyebrow (Fig. 2b, F). Fig. 2c 
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shows results from a separate experiment in which female MRL/+ mice that had 
received 2 (instead of 3) injections of DC/nec also developed such typical facial 
lesions, thought at much a later stage (Fig. 2c, 11-months post injection). In a total of 
10 DC/nec-treated female MRL/+ mice from 3 separate experiments (n = 3, 3, 4; 
treatment started at the age of 11-week), 9 developed such lesions including 5 of them 
extensively (results from Exps. I and II are shown in Fig. 2). In contrast, no such 
lesion was observed in mice treated with DC/apo, DC, or PBS-treated control group 
(Fig. 2a, 2c), or in necrotic cells alone (Nec) or apoptotic cells alone (Apo) treated 
groups (data not shown). Neither male MRL/+ mice (Fig. 2b, M) nor C57BL/6 mice 
of either sex that received DC/nec or DC/apo developed the rash. Some localised 
facial lesions were also seen early on in the DC/nec-treated MRL/lpr mice similar to 
those observed in the IL-18-treated MRL/lpr mice reported by us previously [16]. 
However, the lesions were less extensive than those observed in the DC/nec-treated 
MRL/+ mice, probably because the MRL/lpr mice died soon after the treatment, 
before the lesions could fully develop.  
 
Histological examination of the affected skin showed a focal lymphohistiocytic 
infiltrate in the interstitium of the papillary dermis and around the bulbs of hair 
follicles (Fig. 2d [ii], [iii]). Detailed examination of the alopecic skin revealed a 
significant increase in the number of catagen, and decrease in anagen, hair follicles, as 
evidenced by scattered apoptotic bodies in the outer root sheath, disappearance of the 
inner root sheath and progressive thickening, hyalinization and corrugation of the 
vitreous membrane (Fig. 2d[v], and histograms). Anagen and catagen are two types of 
hair follicles at different phases of hair cycling. In normal skin, majority of hair 
follicles are anagens (~90%) which are in the phase of active hair production, while 
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catagens are in the involutionary stage of the hair cycle characterized by the loss of 
mitotic activity being short lasting and development of apoptotic cell death in the 
outer root sheath[17, 18]. The present findings indicate that a process of 
catagenization within the skin with mild peri-bulbar follicular inflammation can be 
induced following such abrupt but transient insults of DC/nec injection. The DC/nec-
induced histopathology, although not exactly the same as the typical chronic lupus 
dermatitis in human disease, is more in keeping with a non-scaring alopecia such as 
the allied autoimmune skin disease of alopecia areata also observed clinically in lupus 
patients [17, 18].   
 
Proteinuria and renal histopathology. 
Glomerulonephritis, the renal involvement caused by immune complex deposition and 
complement activation, is a severe complication of lupus disease and represents the 
major cause of death [19]. We next assessed the renal pathological changes in the DC-
treated mice. MRL/lpr lupus mice develop age-dependent spontaneous and 
progressive proteinuria, which is not seen in untreated MRL/+ or C57BL/6 mice up to 
7 months of age (Fig. 3a, right panel). Following injection of DCs, however, high 
levels of proteinuria were observed in the DC/nec-treated MRL/+ mice (Fig. 3a, left 
panel), at levels similar to those seen in aged MRL/lpr mice (5-6 months, female, 
right panel) with overt clinical disease, but not in the similarly treated C57BL/6 mice. 
In contrast, significantly lower levels of proteinuria were detected in MRL/+ mice 
treated with DC/apo, DCs alone (DC), apoptotic (Apo) or necrotic (Nec) cells alone. 
Acceleration in proteinuria development was also observed in MRL/lpr mice 
following injection of DC/nec. However, unlike the MRL/+ mice which gradually 
recovered after cessation of treatment, the MRL/lpr strain developed progressively 
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severe proteinuria and died early. Light microscopy showed cellular proliferation in 
the glomeruli (glomerular hypercellularity) of female MRL/+ mice treated with 
DC/nec but not with DC/apo (data not shown). Immunostaining for IgG revealed 
substantial immune complex (IC) deposition in kidneys of the DC/nec-treated, but not 
the DC/apo-treated, female MRL/+ mice (Fig. 3b). Such deposits were found mainly 
within the affected glomeruli, some were focalised around the hilar region (Fig. 3b[i]) 
while others were more diffusely distributed (Fig. 3b[ii]). This was further confirmed 
by electron microscopy showing large electron dense deposits in the mesangial areas, 
with expansion of the mesangium (Fig. 3c, arrows). The DC/nec-induced renal 
pathology and proteinuria were generally more prominent and appeared earlier in 
female than male MRL/+ mice, but such gender differences were less clear cut for the 
MRL/lpr strain. No lymph node enlargement or splenomegaly was found in treated or 
untreated MRL/+ and C57BL/6 mice. No gross pathology was detected in the joints, 
lungs, heart and liver of these mice. 
 
Anti-dsDNA antibody isotype and DC cytokine expression profile. 
The lupus-like disease induced in the wild type control MRL/+ strain following 
treatment with DC/nec can be first explained by the strong anti-dsDNA responses, 
which reached levels similar to those seen in terminally ill MRL/lpr lupus mice (Fig. 
1 histograms). However, the failure to induce clinical disease (skin lesions, 
proteinuria and renal pathology) in C57BL/6 mice by DC/nec or DC/apo, despite the 
presence of considerable levels of anti-DNA antibodies (Fig. 1 upper right panel), 
prompted us to analyse the potential contribution of the anti-dsDNA antibody isotypes 
so-induced in disease induction, and the DC functional activities upon interactions 
with different types of dying cells.  
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To investigate the mechanisms underlining these different effects observed above, DC 
functional phenotypes and their abilities to produce cytokines including the Type I 
(IFN-γ, IL-12, IL-23, IL-18) and Type II (IL-4, IL-5, IL-10) related cytokines 
following ingestion of dying cells were examined. After triggering by necrotic cells, 
DCs showed marginal up-regulation of MHC class II, CD80, CD86 and CD40 (data 
not shown). Although these DCs did not spontaneously secrete significant amount of 
most of the cytokines mentioned above (Fig. 4a open bars), their responsiveness to 
further stimulation altered dramatically. Shortly after stimulation with LPS (16h), 
DC/nec but not DC/apo or control DCs (DC) from MRL/+ mice secreted large 
amounts of IFN-γ, producing up to 53 folds more IFN-γ than the similarly stimulated 
control DCs, together with a moderately increased IL-10 activity (Fig. 4a left panels, 
filled bars). In contrast, whereas control DCs from C57BL/6 mice produced some 
levels of IFN-γ, DC/nec from this mouse strain displayed a suppressed IFN-γ activity, 
yet the production of IL-10 instead was much enhanced (Fig. 4a right panels, filled 
bars). No or only background levels of IFN-γ and IL-10 were detected in cultures of 
either necrotic or apoptotic cells alone, in the presence (Fig. 4b) or absence (data not 
shown) of LPS. Kinetic study indicated that the differences in IFN-γ level did not 
correlate with differences in IL-12 activity, and the early phase of IFN-γ release by 
MRL/+ DC/nec in particular was independent of IL-12 activity (Fig. 4b). Fig. 4b also 
shows that IL-12 p70 production by DC/nec and DC/apo from both MRL/+ and 
C57/BL6 strains of mice is significantly suppressed instead when compared to that of 
DCs alone (DC). In addition, the production of IFN-γ did not correlate with IL-12/IL-
23 (p40) and IL-18 activities either, and only low levels of IL-4 and IL-5 were 
detected in the DC cultures tested (data not shown). 
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We next studied the in vivo relevance of the above findings. Isotypic analysis of the 
serum anti-dsDNA antibodies revealed that certain isotypes of these autoantibodies 
were differentially induced in the mouse strains following treatment with DC/nec, 
DC/apo or DC. As shown in Fig. 5a, anti-dsDNA antibodies of the IgG1 isotype were 
readily detectable in the treated mice of both MRL/+ and C57BL/6 strains, as well as 
the IgM and IgG2b isotypes in the treated C57BL/6 mice. However, the levels of 
these antibodies were generally comparable among the three differently treated groups 
of either strain. In contrast, in the MRL/+ mice, serum levels IgG2a anti-dsDNA 
antibody levels were significantly higher in the DC/nec-treated mice (Fig. 5a, IgG2a, 
left panel), compared to that of DC/apo or DC alone treated groups. Such enhanced 
IgG2a anti-dsDNA response was however not seen in similarly treated (DC/nec) 
C57BL/6 mice (Fig. 5a, IgG2a, right panel). This was further confirmed by using a 
monoclonal antibody (Clone R19-15, BD Biosciences, San Jose) which was raised 
against C57BL/6 IgG2a antibody subclass (data not shown). The close correlation of 
the heightened IFN-γ activity (Fig. 4), enhanced anti-dsDNA IgG2a antibody 
production (Fig. 5a), and the disease development (Figs. 2, 3) induced by DC/nec in 
MRL/+ mice suggests a potential role of Th1 type of response in lupus pathogenesis, 
since IFN-γ is the prototypic Th1 cytokine important for IgG2a antibody isotype 
switching [20]. 
 
We then also carried out detailed assessments of the renal ICs using IgG1 and IgG2a 
isotype-specific antibodies. This revealed that ICs containing IgG1 and IgG2a were 
both present in the kidneys of DC/nec-treated MRL/+ mice. There was no significant 
difference in the frequency of IgG1 ICs between the mice treated with DC/nec and 
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with DC/apo. However, kidney sections from the DC/nec-treated female MRL/+ 
disease mice exhibited strong IgG2a positive glomerular deposits with a frequency 
significantly higher than those from mice treated with DC/apo or untreated control 
mice (Fig. 5b, histograms). More importantly, whereas the IgG1 ICs were generally 
weaker and more diffusely distributed, the IgG2a ICs were much stronger and 
focalised around glomerular hilar regions (Fig. 5b photograph, in red), a pattern 
similar to that seen in aged MRL/lpr mice. By comparison, minimal IC deposits for 
both IgG1 and IgG2a were detected in the DC/nec and DC/apo-treated C57BL/6 mice. 
Similar results were obtained by using the isotypic (IgG2a) specific polyclonal (Fig. 
5b) and the R19-15 monoclonal (data not shown) antibodies.  
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Discussion 
Our present findings show that systemic autoimmune responses including anti-
dsDNA antibodies and tissue immunopathology can be induced in vivo by DCs that 
have acquired nuclear antigens derived from somatic dying cells, especially of the 
necrotic form. This is intriguing because necrotic cell death is usually associated with 
inflammation or infection, and many autoimmune diseases are indeed accompanied or 
induced by chronic infections [21]. The maturation and activation state of DCs is 
known to be critical in determining their immuno-adjuvanticity, which can be 
enhanced by pro-inflammatory stimuli such as bacterial products (e.g. LPS) as well as 
cellular contents released by necrotic cells (“endogenous danger signals” [22-25]. In 
contrast, apoptotic cell death is generally associated with normal tissue turnover or 
removal of virally infected, tumour or other unwanted cells in a controlled manner [26, 
27]. During such programmed cell death, toxic cellular contents are largely degraded 
and normally prevented from extensive exposure to the immune system. In agreement 
with these notions, uptake of necrotic, but not apoptotic, tumour cells by DCs has 
been shown to trigger DC maturation resulting in up-regulation of co-stimulatory 
molecules and antigen-presenting activity of the cells [22, 28], and to enhance the 
antitumor immunity [29]. Injection of apoptotic thymocytes or DCs primed with 
apoptotic thymocytes failed to induce clinical disease in non-autoimmune mice, 
despite an anti-DNA response being elicited [9, 30]. Apoptotic cells may develop to 
become secondary necrotic if not removed timely [31]. It is possible that the limited 
responses of DCs loaded with apoptotic cells observed here and in these previous 
studies are due to secondary necrotic changes in cells resulted from handling 
processes, and that have exceeded the dying cell removal threshold. Another 
possibility is that the apoptotic and necrotic cell preparations may contain different 
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amounts of nuclear antigens contributing to the observed differential induction of 
anti-DNA responses. However, total DNA purified from the two types of dying cells 
was found to be comparable following incubation at 370C for 3 hrs (before co-
culturing with DCs). After an overnight incubation that was at the time immediately 
before injection, the amount of DNA recoverable from the cultured necrotic cells 
(10.06+1.16 µg, per 5 million cells of origin) was no more than that of apoptotic cells 
(14.38+0.96 µg). Nevertheless, we provide direct evidence here that, unlike MRL 
DCs that have been conditioned by necrotic cells, apoptotic cell-loaded DCs induce 
only low level of anti-DNA antibodies, especially of the IgG2a isotype, in vivo and 
are insufficient to cause systemic disease in the mouse models studied. 
 
The uptake of necrotic cells that provides both the nuclear antigens and the 
endogenous signals for DC maturation may account for their ability to induce anti-
DNA antibody response in vivo. We also show here that MRL DCs after being primed 
by necrotic cells are hypersensitive to LPS stimulation to produce high levels of IFN-
γ in vitro. IFN-γ is a Th1 cytokine known to be crucial for IgG2 antibody isotype 
switching in mouse. Therefore, both endogenous and exogenous signals appear to be 
required for the DCs to mediate such a Th1 type response, and this may explain the 
ability of these cells to induce preferentially IgG2a anti-dsDNA antibodies in vivo. 
However, the direct in vivo relevance of LPS to the present experimental model is still 
yet to be established, which may be associated with the role of environmental 
pathogens. All the animals on experimental schedule in the present study shown were 
housed in conventional animal facility, and it will be interesting to compare them with 
those kept under specific pathogen free or even germ-free condition in future studies. 
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IgG2 anti-DNA antibodies are thought to be more pathogenic than other subclasses 
for many of their immunophysiological features [13, 32-34]. A switch from IgM to 
IgG2a and IgG2b subclasses has been previously shown to herald the onset of severe 
disease in the NZB/W lupus-prone mouse model [35] and, more recently, these IgG2 
anti-dsDNA antibodies were found to be more frequently present in lupus patients 
with renal disease [36]. The lack of clinical manifestations in the DC/nec-treated 
C57BL/6 mice despite significant serum anti-dsDNA total IgG (Fig. 1) levels, which 
is also in agreement with a recent report [37], may therefore be explained by 
differences in the quality of the antibody responses induced (Fig. 5). The unique 
induction of IgG2a anti-dsDNA response exclusively in the DC/nec-treated mouse 
group of the MRL/+ but not C57BL/6 strain (Fig. 5a), which is consistent with the 
very antibody isotype associated with the immune complex deposits readily detectable 
in the affected kidneys (Fig. 5b), indicates that a Th1 type of response induced in vivo 
may be essential for the development of clinical disease. We have shown previously 
that systemic injection of the Th1-related, pro-inflammatory cytokines IL-12 or/and 
IL-18, accelerated lupus disease progression in MRL/lpr mice [16, 38]. IL-12 and IL-
18 are generally thought to act by stimulating T cells and NK cells to produce IFN-γ, 
but recent evidence indicates that, apart from T (Th1) and NK cells, DC may also be a 
direct source of IFN-γ [39]. Here we show that DC/nec from MRL/+ mice may 
release directly high levels of IFN-γ independent of IL-12 and IL-18 activities. IFN-γ 
may also contribute directly to the lupus pathology by activating macrophages to 
produce elevated level of nitric oxide which has also been strongly implicated in the 
lupus pathogenesis [38]. Furthermore, type I interferons (IFN-α/β) are known to play 
important roles in SLE pathogenesis[40]. In particular, IFN-alpha has been shown to 
induce DC differentiation driving autoimmune response in SLE [41]. It will therefore 
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be interesting to determine whether the expression of these cytokines may also be 
modulated in DCs upon interactions with dying cells. 
 
In a normal immune system, the expression of the pro-inflammatory cytokines is 
under tightly controlled regulatory mechanisms. IL-10 is a potent immunosuppressive 
cytokine controlling Th1 responses. Elevated serum IL-10 levels have been associated 
with lupus disease activity [42]. This may reflect a desperate yet failed attempt of the 
immune system to down-regulate the autoimmune responses. We show here that, in 
response to LPS stimulation, DC/nec from C57BL/6 mice produce much elevated 
levels of IL-10. The differences between MRL/+ and C57BL/+ strains of mice in the 
levels of IL-10 activity induced (Fig. 4) suggest that such feedback regulatory 
mechanism may be lacking in the MRL mice. Taken together, these findings suggest 
that, upon triggering by inflammatory stimuli, DC/nec from MRL/+, but not C57BL/6, 
mice produce high levels of IFN-γ mediating a Th1-biased response. Consequently, 
this may result in elevated IgG2a auto-antibody synthesis leading to the lupus-like 
pathological changes. The failure to induce a Th1-biased anti-DNA response in the 
C57BL/6 mice may explain the absence of clinical disease in this mouse strain, 
possibly reflecting a strong negative feedback regulatory mechanism depending at 
least in part on IL-10 activity. In addition and in agreement with what is commonly 
seen in autoimmunity, the gender differences (anti-DNA response, skin and renal 
pathology) observed in the present study indicate that the sex hormones also play a 
role in the DC-induced autoimmune responses. 
 
The genetic basis of SLE is complex, involving contributions from multiple genes 
[43]. The MRL/lpr mouse strain is a widely used classical animal model for human 
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SLE. Lpr, identified as a mutation in Fas (CD95), interferes with T cell maturation 
and normal cell renewal process, allowing the release of auto-reactive T cells into the 
periphery and possibly the generation of ‘bad’ cell death [10]. Homozygosity for lpr 
results in a severe lupus-like disease in these mice [14]. However, other lpr congenic 
strains of mice that possess the lpr mutation develop lymphoproliferation but not 
always the lupus disease, depending on their genetic background [44]. At least two 
additional susceptibility loci in the MRL background have been mapped which are 
associated with nephritis [45]. We show here that anti-DNA responses followed by a 
lupus-like disease can be induced in the susceptible MRL/+ mouse strain independent 
of the Fas defect, and without the associated lymphoproliferation. Our present 
findings are based on the murine models and how these may be translated into the 
human disease is an important issue remains to be addressed. Our observations also 
suggest that while it is possible to induce autoimmunity by “DC vaccination" in 
susceptible individuals, this is insufficient to sustain a chronic disease and that in the 
absence of continuous "antigen stimulation" disease progression eventually subsides. 
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Materials and Methods 
Mice 
MRL/MpJ-lpr/lpr (MRL/lpr), MRL/MpJ-+/+ (MRL/+) and C57BL/6 strains of mice 
were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and set up as 
breeding pairs in the Specific Pathogen Free Laboratory Animal Unit, University of 
Hong Kong Medical School. Animals undergoing experimental procedures were kept 
in a conventional animal facility. All experiments involving live animals were carried 
out strictly according to the protocol under a licence approved by the Committee on 
the Use of Live Animals in Teaching and Research (CULATR 550-01), the 
University of Hong Kong. 
 
DC generation and uptake of dying cells in vitro 
DCs were propagated from mouse bone marrow precursors for 7 days in medium 
containing murine GM-CSF (2% culture supernatant of the X63-Ag8 cell line kindly 
provided by Professor A Neil Barclay and Mr. MJ Puklavec, the MRC Cellular 
Immunology Unit, Sir William Dunn School of Pathology, Oxford) and IL-4 (4 ng/ml, 
PeproTech EC Ltd, London). Necrotic cells were generated by freezing (-80 0C, 12 
minutes) and thawing (37 0C) syngeneic splenocytes (optimised to obtain maximum 
cell death without cell lysis) and necrosis confirmed by trypan blue staining. 
Apoptotic cells were prepared by UV irradiation (200 mJ/cm2) followed by 3 hours 
culturing at 37 0C, and cell death assessed by propidium iodide incorporation and 
annexin-V staining (PharMingen). The generation of apoptotic and necrotic cells was 
optimized by varying the dose of UV light for apoptotic cells and the numbers of 
freeze-thaw cycles as well as freezing time for necrotic cells. The optimised final 
conditions used for the study were: for apoptotic cells by UV irradiation at 200 
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mJ/cm2/s, followed by 3h culture in serum free medium; and for necrotic cells by one 
cycle of freezing at -800C in fixed volume aliquots (0.5ml) and thawing in water bath 
at -370C. Bone marrow DCs were then co-cultured overnight with the dying 
splenocytes (1:5 DC:dying cells) in vitro. Typically 60~70% of DCs (MHC class II+ 
and CD11c+) took up either necrotic or apoptotic cells (assessed by pre-labelling of 
the cells with CFSE) with similar efficiency as determined by flow cytometry (data 
not shown). DCs were then enriched by a single step density separation (NycoPrep 
1.068, Oslo, Norway). For some experiments, DCs were further purified by using 
MACS bead-conjugated antibodies specific for mouse CD11c (Miltenyi Biotec, UK). 
DC purity and functional phenotypes were assessed by flow cytometry using 
antibodies to DC surface markers (MHC class II, CD11c, CD80, CD86 and CD40), 
and by their cytokine expression profiles (see below). To quantify DNA contents of 
the dying cells after overnight culture at 370C, the apoptotic and necrotic cells were 
sampled, lysed and the total DNA purified using a commercial DNA purification kit 
(QIAamp, QIAGEN, Valencia, USA) before the DNA concentrations were measured 
at 260nm on a UV spectrophotometer. 
 
Cell adoptive transfer 
One million DCs loaded with either necrotic or apoptotic cells, or DCs alone; or 5 
million apoptotic or necrotic cells alone, were injected in PBS intravenously into each 
mouse. Three or two injections were given at 14 days intervals starting at the age of 4 
to 5-weeks (young) or of 11-weeks (adult). 
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Detection of anti-DNA responses 
The mice were bled every two weeks by retro-orbital puncture under halothane 
anesthesia and serial dilutions of the sera tested for anti-DNA antibodies using 
standard ELISA protocols [46] for the detection of anti-dsDNA and anti-ssDNA 
antibodies. DNA antigen: Type I calf thymus DNA (Sigma, D-1501). For anti-dsDNA, 
the DNA-coated plates were treated with S1 nuclease (3 units/ml, Invitrogen, 18001-
016) for 90 minutes at RT. Isotype-specific secondary antibodies for murine IgM, IgG, 
IgG1, IgG2a and IgG2b, conjugated with either horseredish peroxidase (HRP-goat 
anti-mouse IgM or IgG; Sigma, Saint Louis, USA) or alkaline phosphatase (AP-rabbit 
anti-mouse IgG1, IgG2a or IgG2b; Zymed, San Francisco), were used at optimum 
concentrations as determined individually by pre-titration.  Serum anti-DNA levels 
were titrated (serial 4 fold dilutions) and presented as arbitrary units determined by 
using pooled sera from terminally ill aged (5-6 months) MRL/lpr mice as the standard, 
which was set as (units per ml): 1,000 (total IgG) and 100 (IgG1, IgG2a, IgG2b or 
IgM) for anti-dsDNA; and 10,000 for anti-ssDNA (total IgG). The standard sera were 
stored at -80 0C in aliquots and used as an internal quantitative reference throughout 
the study. 
 
Cytokine measurements 
Cytokine production by DCs in vitro with or without dying cell treatment (as 
described above), both spontaneously or in response to LPS stimulation (5µg per ml 
added 4 hours after co-culture with dying cells), was determined by using commercial 
ELISA kits for murine IL-12 (p70), IL-12/IL-23 (p40), IL-18, IFN-γ, IL-10, IL-4 and 
IL-5 (OptEIATM sets; BD Biosciences, San Diago, CA, USA). Samples (culture 
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supernatants) were collected from replicated cultures at different time intervals (3, 16, 
24, 48 and 72 hours after LPS stimulation) and measured without dilution. 
 
Clinical and pathological assessments 
Proteinuria and hematuria were assessed using a commercially available kit (Multistix, 
Bayer Diagnostic, South Wales, UK), graded according to manufacturer’s instructions 
and shown as mg/dL: 0 (negative), 10 (trace), 30 (+), 100 (++), 300 (+++) and 1000 
(++++). At the end point of each experiment, the mice were sacrificed and tissues 
collected including skin, kidneys, spleen, lymph nodes, liver, joints, hearts and lungs. 
Tissues were fixed in 4% buffered formaldehyde, embedded in paraffin, and sections 
stained with H&E for histological examinations. Glomerular cellularity was analysed 
by a computer-assisted program: a sector of renal cortex showing about 40 glomeruli 
was randomly selected from each kidney section. The four largest glomeruli within a 
selected sector were individually photographed using a digital photomicrographic 
system (Nikon Digital Camera System DXM1200). Images were captured at a 
resolution of 2560x2048 pixels. Glomerular size was measured by manual tracing of 
the capsular basement membrane on the computer image of a glomerulus using a 
mouse device under ImageJ v1.30 (Wayne Rusband, National Institutes of Health, 
U.S.A.). Glomerular cellularity was assessed by counting the number of nuclei within 
a defined unit area. Renal Ig deposits were assessed on frozen kidney sections by 
immunostaining using either FITC-conjugated anti-mouse IgG (Sigma, USA), or AP-
conjugated rabbit anti-mouse IgG1 or IgG2a (Zymed, San Francisco) followed by the 
alkaline phosphate substrate, new fuchsin, naphthol AS-B1 and 2-amino-2-
methylpropan-1,3 diol with levamisole to block the endogenous alkaline phosphatase 
activity. For electron microscopy (Philips CM100), tissues were fixed in 2.5% 
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gluteraldehyde, embedded in Epoxy resin, stained with uranyl acetate and lead citrate. 
For immunocytochemistry, the tissues were snap frozen and embedded in OCT 
compound (Tissue Tek, Sakura Finetek, USA). For lymphocyte phenotypic analysis, 
splenocytes and lymph node cells were stained with antibodies to T (CD3, CD4, CD8) 
and B (CD19) cell markers (BD PharMingen) and analysed by flow cytometry. 
 
Statistics: Student’s T test was used throughout for statistical analysis, and considered 
p value < 0.05 (*) being significant and < 0.01 (**) highly significant. 
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Figure legends 
Figure 1 Anti-dsDNA responses induced in vivo following adoptive transfer 
of DCs in young and adult mice. Adult (11-weeks of age) female mice of 3 different 
strains were injected 3 times (arrows) at 14 days intervals with one million DCs that 
had been fed with either necrotic (DC/nec) or apoptotic (DC/apo) cells, or with DCs 
alone (DC), necrotic cells alone (Nec), apoptotic cells alone (Apo), PBS only (PBS) or 
without treatment (Control). Serum samples were taken at Week 0 then bi-weekly 
intervals thereafter the first injection, and tested by ELISA for anti-dsDNA antibodies 
(IgG). Data shown are means ± SEM calculated from individual mice of each group 
to illustrate changes in time kinetics (curves, n = 3~5). For graphic clarity, data for 
DC alone, dying cell alone and PBS treated groups (MRL/+ strain) only at 4-week-
post-injection are shown in comparison (histograms, data combined from 2 
experiments, n = 6). Antibody titres in sera from aged-terminally-ill female MRL/lpr 
mice (n = >20) are shown for comparison. * or * p<0.05, ** or ** p<0.01; * depicts 
significant difference between DC/nec and DC/apo-treated groups, and * depicts 
significant difference between the indicated treated and other treated or untreated 
control groups as determined by the Student’s T test). (†) depicts the time point of 
>50% mortality observed. 
 
Figure 2 Facial lesions manifested in female MRL/+ mice following 
treatment with DC/nec. 11-week female (a, c, d; & b labelled F) and male (b, 
labelled M) MRL/+ mice were injected for 3 times (a, b, d), or 2 times (c), with 
DC/nec, DC/apo, DC as described in Fig. 1. a. 18-weeks after injection, lupus-like 
facial skin lesions were observed in all (n = 3) female mice injected with DC/nec 
(upper panel), but not DC/apo, DC or PBS-treated (Control) mice; b. At 22-weeks 
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post-treatment, all 3 female (F) MRL/+ mice treated with DC/nec developed full-
blown facial skin lesions (Exp. I), but similarly treated male (M) mice were all free of 
such skin lesion. c. In a separate experiment (Exp. II), female MRL/+ mice were 
injected as described above but for 2 times (instead of 3). The facial skin lesions were 
observed again in all of the 3 mice treated with DC/nec (2 of which extensively at 50-
weeks post-treatment), but not in any of the DC/apo-treated mice. d. Skin histology 
(H&E x40): [i][iv] Normal non-alopecic control mouse facial skin showing vertical [i] 
and transverse [iv] sections of normal non-inflamed anagen hair follicles, with inset in 
[iv] highlighting normal majority anagen follicles (x100); [ii] focal lymphohistiocytic 
infiltrate (circled) in interstitium of papillary dermis of a DC/nec-treated mouse; [iii]  
alopecic facial skin showing two anagen hair follicles with a moderate peribulbar 
follicular lymphohistiocytic infiltrate with inset showing higher power (x100) of an 
affected follicle; [v] alopecic facial skin showing numerous catagen hair follicles with 
three catagen follicles highlighted in inset (arrows, x100). Histograms: statistical 
assessment of hair follicles in skin of different treatment groups (number of catagens 
in 100 hair follicles counted blindly, Mean ± SEM, n = 3,  *p<0.05, ** p<0.01, 
Student’s T test).  
 
Figure 3 Proteinuria and glomerular histopathological changes induced by 
DC/nec. a. Proteinuria. Left panel: Female MRL/+ and C57BL/6 mice were injected 
with syngeneic DC/nec, DC/apo, DC alone (DC), necrotic (Nec) or apoptotic (Apo) 
cells alone, or PBS (Control) (n = 3~6). Right panel: levels of the spontaneous 
proteinuria developed in untreated MRL/lpr mice at different age (n = 13-25) in 
comparison with that of the MRL/+ and C57BL/6 strains (all females). Proteinuria 
was monitored bi-weekly (see Methods). Data shown (mg/dL) are means ± SEM, 
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calculated from individual mice of each group. ND: not done. b. Immunostaining for 
total IgG (fluorescent microscopy): Ig deposits were assessed on frozen kidney 
sections after staining with a FITC-conjugated goat-anti-mouse IgG antibody, and 
examined by confocal microscopy. Both focal [i] and global [ii] staining patterns were 
seen in the affected glomeruli of the DC/nec-treated female MRL/+ mice. c, Electron 
microscopy confirmed large electron dense deposits present in the glomerular 
mesangial regions only in the DC/nec-treated mice (arrows, scale bar = 2 µm). 
*p<0.05, **p<0.01 (Student’s T test).  
 
Figure 4 Comparison of the cytokine expression profiles of DC/nec from 
MRL/+ and from C57BL/6 mice.  a. Differential IFN-γ and IL-10 production by 
DC/nec from MRL/+ and C57/BL6 mice in response to LPS. DCs were generated in 
vitro from mouse bone marrow precursors, enriched by density separation (NycoPrep 
1.068) and co-cultured with necrotic (DC/nec) or apoptotic (DC/apo) cells as 
described previously (see Methods). Culture supernatants were collected from the 
DC/nec, DC/apo and control DC alone (DC) cultures, with (filled bars) or without 
(open bars) LPS stimulation (5ug/ml, added 4 h after cell co-culturing) for 16 hours at 
37 0C. IFN-γ, and IL-10 production was determined by ELISA. b. Kinetics of cytokine 
production. Culture supernatants were collected at time intervals (16, 48, 72 and 96 
hrs) from DC/nec, DC/apo, control DC alone (DC), necrotic cells alone (Nec) or 
apoptotic cells alone (Apo) after LPS stimulation. IFN-γ, IL-10, IL-12 (p70) and IL-
12/23 (p40) production was determined by ELISAs. No or only background levels of 
the cytokines were detected in cultures of necrotic or apoptotic cells alone with LPS. 
Data shown are means ± standard deviations (SD). *p<0.05, **p<0.01 (Student’s T 
test). The experiments were repeated for more than 3 times with consistent results. 
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Figure 5 Isotypic analysis of the serum anti-dsDNA antibodies and renal 
immune complex deposits in the DC-treated MRL/+ and C57BL/6 mice. a. Serum 
anti-dsDNA antibody isotypes. Serum samples were taken from adult female MRL/+ 
and C57BL/6 mice four weeks-post-injection of DC/nec, DC/apo or DC alone, and 
from age-sex-strain-matched untreated mice (Control). Anti-dsDNA antibodies of 
IgG1, IgG2a, IgG2b and IgM isotypes were determined by ELISA using murine 
isotypic specific antibodies (see Methods). Data presented are means ± SEM of 
titration units from individual mice of each group (n = 3). b. Isotypic analysis of renal 
ICs. Renal Ig deposits were assessed by immunostaining using AP-conjugated rabbit 
anti-mouse IgG1 or rabbit anti-IgG2a (positivity shown in red, light microscopy, 
X200). For comparison, ICs positive for IgG1 and IgG2a on kidney sections from 
aged MRL/lpr mice with spontaneous disease are shown in the bottom micrographs. 
NRS: normal rabbit serum (negative control). For statistical analysis (histograms), the 
slides were randomly labelled and scored blindly for numbers of glomeruli positively 
stained for IgG1, IgG2a and total IgG (as indicated). Data shown are means ± SEM 
calculated from individual mice of the same group (n = 3). *p<0.05, **p<0.01 
(Student’s T test). The experiments were repeated for 3 times with consistent results. 
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